This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
by Zacks Equity Research
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
by Zacks Equity Research
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
by Swarup Gupta
The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.
3 Small Biotech Stocks That Almost Doubled in Past Month
by Zacks Equity Research
We take a look at three biotech stocks, prices of which have almost doubled in the past month.
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.
Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress
by Swarup Gupta
The index remained weighed down by trade tensions during a holiday-shortened week.
Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.
Large Cap Pharma Stocks Staging a Comeback in Second Half
by Indrajit Bandyopadhyay
Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
Top Analyst Reports for Pfizer, Salesforce & ADP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Salesforce (CRM) and ADP (ADP).
Mylan Suffers Several Setbacks: What's in Store in 2H18?
by Zacks Equity Research
Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.
Pfizer Discontinues Studies on DMD Candidate Domagrozumab
by Zacks Equity Research
Pfizer (PFE) terminates two clinical studies evaluating pipeline candidate, domagrozumab, in patients with duchenne muscular dystrophy.
Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus
by Zacks Equity Research
Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.